Sao Paulo: Bharat Biotech’s contract with Brazil, already suspended and under several investigations, is facing new scrutiny with the revelations that the Hyderabad-based company had signed a Memorandum of Understanding (MoU) with its Brazilian representative and a Dubai firm, which is not traceable.
The MoU, obtained by Folha de Sao Paulo newspaper, was sent by the Indian company’s Brazil representative, Precisa Medicamentos, to that country’s ministry of health as a proof of their partnership. But the presence of a third company and the date of the agreement has come to the notice of the parliamentary commission of inquiry (CPI) which is digging deeper into the scandal involving the planned supply of 20 million doses of Covaxin in a $300 million deal.
The tripartite MoU, signed on November 24, 2020, four days after the first meeting between Bharat Biotech’s top brass, their Brazilian representatives and health ministry officials, says that Envixia Pharmaceuticals LLC, a company registered in the United Arab Emirates, “would be responsible for providing support for all activities related to the registration and commercialization of Covaxin in Brazilian territory”.
While the role of Precisa Medicamentos in the deal is known – and being probed – this is the first time that the name Envixia, in a crucial role, has cropped up in this scandal.
As per the document, released by Folha de Sao Paulo, the MoU proposes a future contract between three “parties”. While mails sent to Bharat Biotech and Precisa Medicamentos by The Wire remained unanswered, the executive director of the Brazilian firm, Emmanuela Medrades, confirmed to Folha de Sao Paulo that the Dubai company was “indeed” part of the document.
“Envixia’s participation is normal. It was chosen by Bharat [Biotech] to explore the possibilities for the vaccine in Brazil and the United Arab Emirates,” said Medrades, who had travelled to India in January 2021 to sign a contract with Bharat Biotech and also put her name on the pact with the Brazilian government on February 25, 2021.
The clarification from Medrades says little and the executive will surely face a barrage of questions when she appears at the senate hearing on Tuesday (July 13). Precisa Medicamentos is the main target of senators who are looking at its documents with a magnifying glass. The appearance of the MoU, say sources in Brasilia, have opened two new lines of investigation. First, how did the representatives of Bharat Biotech attend an official meeting before signing an MoU with the company? And secondly, what exactly is the role of Envixia in the deal?
As an invoice for advance payment of $45 million sent by Madison Biotech, an offshore firm in Singapore which is not part of the Covaxin contract, has already made the probe follow the money, the appearance of another company, which can’t be located, has also triggered the curiosity of investigators.
The Mumbai connection
Envixia Pharmaceuticals LLC is so elusive that even Google can’t find it.
An internet search for the company’s name shows no results. But inquiries by The Wire suggest the company probably has links with a Mumbai-based firm, Invex Healthcare, whose owner is being investigated by the Uttarakhand Police in the fake COVID-19 tests scandal during the Kumbh Mela in Haridwar.
In the Memorandum of Understanding signed on November 24, 2020, Envixia Pharmaceuticals LLC is mentioned as a company in “International Free Zone Authority, Fujairah – UAE having its registered office at Kidnah, Block A, Plot 4, Fujairah – UAE.”
The publicly available records of the International Free Zone Authority (IFZA), located in Dubai Digital Park, show nothing for Envixia. The records of Dubai Financial Services Authority and National Economic Register, Ministry of Economy, United Arab Emirates, also show no results for this name. The Wire sent a mail to IFZA, asking if a company named Envixia was ever registered with the authority but got no response till the time of original publication.
On Monday, in an email response, the Dubai-based authority confirmed that “Envixia Pharmaceuticals FZCO is registered with IFZA and the license is active”. As FZCO stands for free zone company and the firm mentioned in the MoU is called “Envixia Pharmaceuticals LLC”, with LLC standing for limited liability company, The Wire wrote back to the free zone authority to confirm if companies can register as LLC with IFZA. The Wire also asked the Dubai authority to share the identity of the person in whose name the company Envixia Pharmaceuticals FZCO is registered and when it was done with how much capital? The authority was also asked to confirm if “Anudesh Goyal is registered as a general manager or director of this company”? To this query, IFZA sent a one-line reply: “Unfortunately, we will not be able to share any further information without the consent of the license holder.”
The details in the MoU also raise suspicions about Envixia’s precise status. At the bottom of the document, there are three signatures. On behalf of Bharat Biotech, it is signed by Dr V. Krishna Mohan whose title is written as whole-time director; the witness signature appears to read “Apoorv Kumar”, who, as per other documents seen by The Wire, is a top executive of the company. In the middle column of the MoU, sits the signature of Francisco Maximiano, the president of Precisa Medicamentos. In the third column, the MoU is “signed and delivered on behalf of Envixia Pharmaceuticals LLC” by Anudesh Goyal whose title is written as general manager. Unlike the other two columns, there is no date and company stamp below Goyal’s name. The witness signature in this column appears to be “A Gavande”.
The Wire sent a set of questions on Friday morning to Bharat Biotech and Precisa Medicamentos, asking about their relationship with Envixia and Anudesh Goyal’s role in the supply of vaccines to Brazil, but got no response. An executive of the media wing of Bharat Biotech confirmed the receipt of questions and promised to “forward to (persons) concern (sic) and revert”, but there was no reply, as with the previous queries sent to the company by The Wire in the past few weeks.
It is hard to understand why a company of the size of Bharat Biotech would not respond to a few basic questions about their business partner, especially when their multi-million-dollar contract with Brazil faces a threat of cancellation. But, irrespective of the company’s silence, the names of Envixia and Anudesh Goyal are now on the radar of investigators in the burgeoning scandal.
The trail to Kumbh
For many pharmaceutical executives The Wire spoke to, the name Envixia doesn’t ring a bell. But Anudesh Goyal is not an unknown quantity in pharmaceutical circles in Mumbai and Dubai, where he might have participated at the “Arab Health” event held at Dubai World Trade Centre in January 2020. A Mumbai-based company, Invex Healthcare, which took part in this Dubai gig is headed by one Anudesh Goyal who has his office in Andheri. On its website, Invex Health describes itself as a “fully integrated pharmaceutical company with services extended from delivering pharmaceutical products to pharma mergers and acquisitions”.
On his LinkedIn profile, Anudesh Goyal is listed as the “Director of Invex Health Private Limited”, who is with the company full-time since December 2018, when it was founded. Of the four employees – present and former – on the company’s LinkedIn profile, one is Anagha Gavande who worked as a business development specialist from November 2019 to February 2021.
It is conceivable that two persons with the same names have similar professional profiles. But in this case, the similarities are too many. Not only are the two firms in the same sector (health) and have similar-sounding names – “Envixia” and “Invex” – they are also headed by persons of the same name – Anudesh Goyal.
And the witness signature below Goyal’s in the MoU appears to be “A Gavande”, similar to the name of Anagha Gavande who was employed with the Mumbai firm in November 2020, when the MoU was signed. The Wire sent an email to the address on the company’s website, asking about Goyal’s relationship with Envixia and Bharat Biotech. Two calls made from two different numbers on the mobile phone number of Invex were declined after a few rings. A copy of the mail sent to Anudesh Goyal, was also sent to a WhatsApp number of the company. The message was delivered and seen – indicated by blue ticks – but not replied for more than 24 hours.
The Invex angle has given a completely new twist to the Covaxin story in Brazil. As already reported in the Indian media, a person named Anudesh Goyal has been interrogated by the Special Investigation Team of Uttarakhand Police for “mediating” a pact between two firms which are accused of serious irregularities in COVID-19 tests during the Kumbh Mela.
A senior official of Uttarakhand Police confirmed to The Wire that Anudesh Goyal, whose company is called Invex Health, has been questioned. “We can’t say if he runs a company called Envixia but he certainly has some business in Dubai,” said the official, speaking on the condition of anonymity. “Our focus is the irregularity committed in testing during the Kumbh Mela,” said the official, adding that they had no instructions to look into the Covaxin case.
But based on the MoU document and their own investigation, the Brazilian media published on Friday a couple of reports establishing a connection between Covaxingate in Brazil and the Kumbh Mela fraud in India. The common link in the two cases, as per the reports, being Anudesh Goyal, who hasn’t responded to messages despite repeated attempts by The Wire and Folha de Sao Paulo reporters.
The price of uncertainty
The vaccine controversy, which has made ordinary Brazilians go to the streets in huge numbers to demand President Jair Bolsonaro’s removal from power, has also tarnished the image of Bharat Biotech. The revelations that the company sent an invoice of $45 million into an offshore account without delivering a single dose has damaged its reputation and also made the Covaxin contract the focus of the senate probe. Now, with revelations about a fourth company – from Dubai – the MoU may get as much attention as the Singapore invoice and the contract between the Indian firm and its Brazilian representative.
With their pointed questioning of government officials, the senators leading the probe have been trying to sniff the money trail in CovaxinGate, which many of them have accused to be a “grand corruption scheme” to buy the most expensive vaccine. Bharat Biotech has claimed that it always offered to sell Covaxin for $15 to $20 to international buyers. But the senate probe is looking at an official document that says that the Indian firm had offered to sell its vaccine for $10 a dose to the Brazilian government with the possibility of dropping the price further.
In a meeting held on November 20, 2020, four days before the MoU was signed between the three companies, Bharat Biotech offered a price of $10, as per an official document sent by the ministry of health to the commission. First revealed by Estado de Sao Paulo newspaper, the “Minutes of the Meeting” show that three local representatives of Bharat Biotech attended the meeting in person, while four of its executives had joined via a video link. On the Brazilian government side, Elcio Franco, then executive secretary of the ministry was present with six other officials.
“The price of the vaccine is $10 per dose, which, due to the eventual purchase of a large amounts of doses, could be reduced and would be open to negotiation,” says the document, which lists the commercial and legal aspects of the negotiations.
The document, which was put on a large screen in the senate chamber on July 7, shows the names of Francisco Maximiano and Emmanuela Medrades attending the meeting on behalf of Precisa Medicamentos. For the Indian company, Dr Raches Ella, Sai Prasad, Venkat Hariharan and Apoorv Kumar had joined. While senators from the government side have claimed that the offer of $10 per dose was never made formally, the official document suggests otherwise. The first time that Bharat Biotech mentioned the price of $15 was on January 12, 2021, the day it signed a contract with its Brazilian representative and gave Brazil just three days to accept the offer. The agreement between Brazil and Bharat Biotech was signed for $300 million. The cost to Brazil would be $100 million less, say senators, if the initial offer had been maintained.
The question of how and why the cost of the vaccine went up was the focus of inquiry this week. On Wednesday, as the health ministry’s documents was on the screen in the senate, several senators accused that the extra $100 million in the deal was the amount to be swindled.
With the document still on display, Senator Renan Calheiros, the rapporteur of the commission, trained his guns directly at Bolsonaro. “The Covaxin vaccine was overpriced…This is perhaps the most important finding of the CPI. While rejecting the vaccines from Pfizer and others, the President asked the Prime Minister of India to send 20 million doses…The President not only knew about the swindler’s deal he participated in it…,” said Senator Calheiros in a rare outburst at the session broadcast live and watched by millions.
Bolsonaro’s image, already in tatters, has taken a severe beating with CovaxinGate. A poll released on Thursday showed that his rejection rate has crossed 51%, a new record.
It also showed that the vast majority of the country thinks the president is dishonest. Boxed in by the probe, Bolsonaro has been firing at the Congress and Election Commission, threatening to cancel the election scheduled for 2022. This has provoked a sharp rebuke from the senate chief, Supreme Court judges and political commentators. As the inquiry rolls on, more dirt is certain to come out. And with it will come political uncertainty in Brazil – with Covaxin sitting at the centre of it.
Shobhan Saxena and Florencia Costa are independent journalists based in Sao Paulo, Brazil.
Note: This story was updated on Monday, July 12, 2021, to incorporate the response received from the Dubai Financial Services Authority about Envixia Pharmaceuticals.